A recent study reveals that patients who stop using new slimming jabs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who end conventional lifestyle plans.
Published data in a major medical journal demonstrates that while obese people frequently drop a large proportion of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month after stopping.
"People purchasing these medications need to be cognizant of the potential of quick weight regain when the medication ends," cautioned expert Dr. Susan Jebb.
Such speed of regain implies a reversion to pre-treatment weight within about 18 months.
Analyzing Treatments
The study, which examined dozens of studies involving thousands of participants, contrasted the outcomes of the injectable medications with older methods.
Researchers note that people who lose weight through dieting generally see a less rapid weight regain—perhaps 100 grams monthly—post-intervention.
Explaining the Quick Rebound
Experts believe the mechanism of the jabs explains the accelerated regain.
These medications copy a natural hormone called GLP-1, which controls appetite.
"Long-term administration of GLP-1 concentrations far above than normal may cause the body to produce less of its endogenous GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement leads to hunger is unsuppressed, making binge eating far more likely."
An Ongoing Issue?
The NHS advise the injections for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
Professionals argue that, given the likelihood of weight regain, the therapy is often life-long.
This perspective is reinforced by drug manufacturers, who note that the results "emphasize the persistent nature of excess weight," comparing it to managing conditions like high blood pressure.
User Experiences
People who have stopped the jabs describe a powerful resurgence of cravings.
"It felt as if a switch that goes on and you become ravenous," described a patient.
This difficulty is compounded if patients have not developed permanent lifestyle or habit changes during therapy.
Significant Interest
Recent estimates show that millions of people in the UK have used these injections in the past year, with demand being substantial.
- Adoption is greater among women than men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Finally, researchers emphasize that while these medications are effective agents for shedding pounds, they are not a standalone fix and maintained weight loss hinges on integrated behavioural support.
